Cingulate (CING) Common Equity (2021 - 2026)
Cingulate's (CING) quarterly Common Equity came in at $2.5 million in Q4 2025, down 66.35% YoY from $7.5 million in Q4 2024, and down 27.77% on a QoQ basis from $3.5 million in Q3 2025.
Cingulate (CING) Common Equity (2021 - 2026) Analysis & Trends
Cingulate (CING) has 5 years of Common Equity data on file, last reported at $2.5 million in Q4 2025.
- Quarterly Common Equity fell 66.35% year-over-year to $2.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.5 million (down 66.35% YoY) and the FY2025 annual result came in at $2.5 million, down 66.35% from the prior year.
- Common Equity retreated to $2.5 million in Q4 2025, from $3.5 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $20.8 million in Q4 2021 to a low of -$6.9 million in Q4 2023.
- A 5-year average of $4.9 million and a median of $3.3 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2023 — Common Equity slumped 276.95% — and 2024, when it jumped 12595.65%.
- Tracing CING's Common Equity over 5 years: stood at $20.8 million in 2021, then plunged by 81.38% to $3.9 million in 2022, then tumbled by 276.95% to -$6.9 million in 2023, then jumped by 208.53% to $7.5 million in 2024, then tumbled by 66.35% to $2.5 million in 2025.
- The last three Common Equity figures came in at $2.5 million (Q4 2025), $3.5 million (Q3 2025), and $5.5 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Cingulate | 72.85 Mn | 72.85 Mn | - | 23.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.47 Mn |
| Dec 31, 2025 | 2.51 Mn |
| Sep 30, 2025 | 3.47 Mn |
| Jun 30, 2025 | 5.51 Mn |
| Mar 31, 2025 | 5.93 Mn |
| Dec 31, 2024 | 7.46 Mn |
| Sep 30, 2024 | 12.04 Mn |
| Jun 30, 2024 | 3.08 Mn |
| Mar 31, 2024 | 3.22 Mn |
| Dec 31, 2023 | -6.87 Mn |
| Sep 30, 2023 | -96,334.00 |
| Jun 30, 2023 | -6.10 Mn |
| Mar 31, 2023 | 81,614.00 |
| Dec 31, 2022 | 3.88 Mn |
| Sep 30, 2022 | 8.37 Mn |
| Jun 30, 2022 | 12.18 Mn |
| Mar 31, 2022 | 16.02 Mn |
| Dec 31, 2021 | 20.84 Mn |
| Sep 30, 2021 | 3.08 Mn |
| Jun 30, 2021 | 1.90 Mn |